// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Gabriela Schneider1, Ewa Bryndza1, Agata Poniewierska-Baran1, 5, Karol Serwin4, 5, Malwina Suszynska1, Zachariah P. Sellers1, Michael L. Merchant3, Alagammai Kaliappan2, Janina Ratajczak1, Magda Kucia1, 4, Nichola C. Garbett2, Mariusz Z. Ratajczak1, 4, 5 1Stem Cell Institute at the James Graham Brown Cancer Center, University of Louisville, KY, USA 2James Graham Brown Cancer Center, Department of Medicine, University of Louisville, KY, USA 3Kidney Disease Program, Department of Medicine, University of Louisville, KY, USA 4Department of Regenerative Medicine Medical University of Warsaw, Poland 5Department of Physiology, Pomeranian Medical University, Szczecin, Poland Correspondence to: Mariusz Z. Ratajczak, email: mzrata01@louisville.edu Keywords: vitronectin, urokinase plasminogen activator receptor (uPAR), fibrinogen, cancer metastasis, chemotaxis Received: July 18, 2016 Accepted: September 09, 2016 Published: September 13, 2016